Trials / Completed
CompletedNCT00080210
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
A Phase II Study of Multiple Doses of Intravenous Puricase in Subjects With Hyperuricemia and Refractory Gout
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Savient Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout. Subjects must wash out of any uric acid-lowering agents for one week before being dosed, and must refrain from using such agents throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Puricase |
Timeline
- Start date
- 2004-03-01
- Completion
- 2005-02-01
- First posted
- 2004-03-25
- Last updated
- 2013-06-03
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00080210. Inclusion in this directory is not an endorsement.